249 related articles for article (PubMed ID: 24486955)
21. Role of prostaglandin E produced by osteoblasts in osteolysis due to bone metastasis.
Ohshiba T; Miyaura C; Ito A
Biochem Biophys Res Commun; 2003 Jan; 300(4):957-64. PubMed ID: 12559967
[TBL] [Abstract][Full Text] [Related]
22. Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer.
Liu J; Li D; Dang L; Liang C; Guo B; Lu C; He X; Cheung HY; He B; Liu B; Li F; Lu J; Wang L; Shaikh AB; Jiang F; Lu C; Peng S; Zhang Z; Zhang BT; Pan X; Xiao L; Lu A; Zhang G
Sci Rep; 2017 Jan; 7():40487. PubMed ID: 28071724
[TBL] [Abstract][Full Text] [Related]
23. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
[TBL] [Abstract][Full Text] [Related]
24. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
[TBL] [Abstract][Full Text] [Related]
25. DHA is a more potent inhibitor of breast cancer metastasis to bone and related osteolysis than EPA.
Rahman MM; Veigas JM; Williams PJ; Fernandes G
Breast Cancer Res Treat; 2013 Oct; 141(3):341-52. PubMed ID: 24062211
[TBL] [Abstract][Full Text] [Related]
26. Effect of 17β-estradiol on estrogen receptor negative breast cancer cells in an osteolytic mouse model.
Cohen DJ; Patel V; Verma A; Boyan BD; Schwartz Z
Steroids; 2019 Feb; 142():28-33. PubMed ID: 29133279
[TBL] [Abstract][Full Text] [Related]
27. Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway.
Jiang W; Rixiati Y; Huang H; Shi Y; Huang C; Jiao B
Cancer Med; 2020 Nov; 9(21):8173-8185. PubMed ID: 32976685
[TBL] [Abstract][Full Text] [Related]
28. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo.
Bendre MS; Gaddy-Kurten D; Mon-Foote T; Akel NS; Skinner RA; Nicholas RW; Suva LJ
Cancer Res; 2002 Oct; 62(19):5571-9. PubMed ID: 12359770
[TBL] [Abstract][Full Text] [Related]
29. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
[TBL] [Abstract][Full Text] [Related]
30. Epiberberine inhibits bone metastatic breast cancer-induced osteolysis.
Wei C; Shi M; Wang Z; Lan W; Feng N; Zhang F; Liu J; Lang JY; Lin W; Ma W
J Ethnopharmacol; 2024 Jun; 327():118039. PubMed ID: 38479545
[TBL] [Abstract][Full Text] [Related]
31. Parathyroid hormone-related protein (PTHrP)-(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo.
Guise TA; Yin JJ; Thomas RJ; Dallas M; Cui Y; Gillespie MT
Bone; 2002 May; 30(5):670-6. PubMed ID: 11996903
[TBL] [Abstract][Full Text] [Related]
32. The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells.
Sterling JA; Oyajobi BO; Grubbs B; Padalecki SS; Munoz SA; Gupta A; Story B; Zhao M; Mundy GR
Cancer Res; 2006 Aug; 66(15):7548-53. PubMed ID: 16885353
[TBL] [Abstract][Full Text] [Related]
33. Molecular mechanisms of breast cancer metastases to bone.
Guise TA; Kozlow WM; Heras-Herzig A; Padalecki SS; Yin JJ; Chirgwin JM
Clin Breast Cancer; 2005 Feb; 5 Suppl(2):S46-53. PubMed ID: 15807924
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
Yoneda T; Sasaki A; Dunstan C; Williams PJ; Bauss F; De Clerck YA; Mundy GR
J Clin Invest; 1997 May; 99(10):2509-17. PubMed ID: 9153295
[TBL] [Abstract][Full Text] [Related]
35. ABL kinases promote breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling.
Wang J; Rouse C; Jasper JS; Pendergast AM
Sci Signal; 2016 Feb; 9(413):ra12. PubMed ID: 26838548
[TBL] [Abstract][Full Text] [Related]
36. Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling.
Sung B; Oyajobi B; Aggarwal BB
Mol Cancer Ther; 2012 Feb; 11(2):350-9. PubMed ID: 22090419
[TBL] [Abstract][Full Text] [Related]
37. In vivo tibial compression decreases osteolysis and tumor formation in a human metastatic breast cancer model.
Lynch ME; Brooks D; Mohanan S; Lee MJ; Polamraju P; Dent K; Bonassar LJ; van der Meulen MC; Fischbach C
J Bone Miner Res; 2013 Nov; 28(11):2357-67. PubMed ID: 23649605
[TBL] [Abstract][Full Text] [Related]
38. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.
Holland PM; Miller R; Jones J; Douangpanya H; Piasecki J; Roudier M; Dougall WC
Cancer Biol Ther; 2010 Apr; 9(7):539-50. PubMed ID: 20150760
[TBL] [Abstract][Full Text] [Related]
39. A Role for TGFβ Signaling in Preclinical Osteolytic Estrogen Receptor-Positive Breast Cancer Bone Metastases Progression.
Cheng JN; Frye JB; Whitman SA; Kunihiro AG; Pandey R; Funk JL
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923316
[TBL] [Abstract][Full Text] [Related]
40. cAMP-response-element-binding protein positively regulates breast cancer metastasis and subsequent bone destruction.
Son J; Lee JH; Kim HN; Ha H; Lee ZH
Biochem Biophys Res Commun; 2010 Jul; 398(2):309-14. PubMed ID: 20599715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
